Pharma Inc gears up for Day 1 launch of obesity drug in March 2026

With semaglutide patents set to expire in 2026, Indian pharma giants are ramping up peptide production and device tie-ups to seize the GLP-1 obesity drug opportunity

​With semaglutide patents set to expire in 2026, Indian pharma giants are ramping up peptide production and device tie-ups to seize the GLP-1 obesity drug opportunity